New Treatment Options in HER2 NSCLC: Expert Insights for Optimizing Therapy with Zongertinib

A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.

Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.

The FDA has approved lirafugratinib (Lyrfigtu) for the treatment of adult patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.

An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.

Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.

Clinicians and researchers are set to gather for the UCSF-cosponsored International Invasive Lobular Carcinoma Symposium.

SOT106 now holds both orphan drug and fast track designations across soft tissue sarcoma and osteosarcoma ahead of a first-in-human trial.

Shailender Bhatia, MD, discusses ADAM trial design, key efficacy and safety findings, and treatment implications in Merkel cell carcinoma.